NFKB1 and Miyoshi myopathy: To determine whether the p52 enhancer landscape is similarly activated in primary tumours from MM patients, we used 26 MM and 3 plasmablast (PB) samples for which H3K27ac ChIP-seq or ATAC-seq data were available and performed complementary RNA-seq where necessary to group these samples by NF-κB index (as performed for the MMRF data) (Fig. 2e)19,20.